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Objective: To evaluate the safety and technical success rate of an ultrasound-guided fiducial marker implantation in 
preparation for CyberKnife radiation therapy.
Materials and Methods: We retrospectively reviewed 270 percutaneous ultrasound-guided fiducial marker implantations in 
77 patients, which were performed from June 2008 through March 2011. Of 270 implantations, 104 were implanted in 
metastatic lymph nodes, 96 were in the liver, 39 were in the pancreas, and 31 were in the prostate. During and after the 
implantation, major and minor procedure-related complications were documented. We defined technical success as the 
implantation enabling adequate treatment planning and CT simulation.
Results: The major and minor complication rates were 1% and 21%, respectively. One patient who had an implantation in 
the liver suffered severe abdominal pain, biloma, and pleural effusion, which were considered as major complication. 
Abdominal pain was the most common complication in 11 patients (14%). Among nine patients who had markers inserted 
in the prostate, one had transient hematuria for less than 24 hours, and the other experienced transient voiding difficulty. 
Of the 270 implantations, 261 were successful (97%). The reasons for unsuccessful implantations included migration of 
fiducial markers (five implantations, 2%) and failure to discriminate the fiducial markers (three implantations, 1%). Among 
the unsuccessful implantation cases, six patients required additional procedures (8%).
Conclusion: The symptomatic complications following ultrasound-guided percutaneous implantation of fiducial markers are 
relatively low. However, careful consideration of the relatively higher rate of migration and discrimination failure is needed 
when performing ultrasound-guided percutaneous implantations of fiducial markers.
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INTRODUCTION
The CyberKnife system is a non invasive image-guided 
frameless robotic radiosurgery modality considered to be 
an alternative to conventional surgery for the treatment of 
both cancerous and non-cancerous tumors (1). Nowadays, 
the system is widely used for extracranial lesions, such as 
lesions in intra-abdominal organs or lung lesions. As the 
lesions are movable on respiration, they are tracked by 
the circumstantial insertion of fiducial markers, which also 
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helps plan the CyberKnife treatment. According to previous 
studies by Sotiropoulou et al. (2) and Kothary et al. (3), 
fiducials have usually been placed under CT-guidance. Due 
to the safety and efficacy of fiducial implantation have 
also been reported to be placed under CT-guidance only. 
However, trans-abdominal or trans-rectal ultrasound-
guided fiducial marker implantation has been performed 
for intraperitoneal or pelvic tumors. We also evaluated 
the placement of fiducial markers under US-guidance 
with respect to safety and technical success rate in the 
preparation for CyberKnife radiation therapy.
MATERIALS AND METHODS 
Patients
Our institutional review board approved this retrospective 
study. From June 2008 to Mar 2011, 77 consecutive 
patients (Men: 45, Women: 32, mean age: 60 years old, 
range: 36-79) who had undergone percutaneous ultrasound-
guided fiducial marker implantations for CyberKnife therapy 
(Accuray, Inc., Sunnyvale, CA, USA) of the intra-abdominal 
organs were enrolled in this study. All the patients elected 
to undergo CyberKnife radiation therapy after having 
a discussion with a radiologist, radiation oncologist, 
and oncologist. We implanted 270 fiducial markers into 
77 patients (number of fiducials: two to six fiducial 
implantations/patient mean: 3.4 in the prostate, 3.5 in 
other sites including). Among the 270 implantations, 104 
were inserted in the metastatic lymph nodes (32 patients), 
96 were inserted in the liver (24 patients), 39 were inserted 
in the pancreas (12 patients), and 31 were inserted in the 
prostate (nine patients). The mean size of the target tumor 
had a maximum diameter of 3.3 cm.
Two-hundred twenty-two fiducial markers in 64 patients 
were inserted via the trans-abdominal route whereas 48 
fiducial markers in 13 patients were inserted via the trans-
rectal route. 31 fiducial markers in the prostate glands of 
nine patients, and 17 fiducial markers in the metastatic 
lymph nodes in the pelvic cavity of four patients were 
implanted under trans-rectal ultrasound guidance (Table 1).
Fiducial Marker Implantation
All the fiducial marker implantations were performed by 
a gastrointestinal radiologist with 13 years of experience. 
By reviewing the previous diagnostic imaging studies 
for methods such as computed tomography, the best 
percutaneous needle approach was planned and fiducial 
insertion was performed under ultrasonographic guidance 
(IU 22, Philips, Einthoven, Netherlands) with a convex 
probe (2-5 MHz) at transabdominal ultrasonography and an 
endorectal probe (5-9 MHz) at transrectal ultrasonography. 
A free-hand style was used for the transabdominal 
ultrasonography, and needle guidance was used for the 
transrectal ultrasonography. 
The skin entry site, which was kept sterile following 
disinfection with betadin, was prepared, and local 
anesthesia (lidocaine 1%, 10 mL) was administered. Under 
Table 1. Summary of Patient Demographics
Parameter Value
No. of 
Fiducial 
Markers
Total patient 77 270   
Men 45
Women 32
Mean age (yr)
60  
(range; 36-79)
Mean tumor size (cm) 3.33
Liver (Trans-abdominal USG) 24 96
HCC 8 32
Cholangiocarcinoma 3 11
Pancreas ca. metastases 4 13
Colon ca. metastases 4 19
GB ca. metastases 2 8
Breast ca. metastases 2 9
Stomach ca. metastases 1 4
Metastatic lymph node 32 104
Trans-abdominal USG 27 87
Stomach ca. metastases 5 17
HCC metastases 4 12
Ovarian ca. metastases 4 13
Colon ca. metastases 3 10
Pancreatic ca. metastases 3 10
GB ca. metastases 3 10
Others 5 15
Trans-rectal USG 5 17
Colon ca. metastases 3 11
Ovarian ca. metastases 2 6
Pancreas (Trans-abdominal USG) 12 39
Adenocarcinoma 10 32
IPMN 1 3
Islet cell tumor 1  4
Prostate gland  
(Trans-rectal USG)
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Ultrasound (US)-guidance the radiologist placed two to 
six gold pins (A fiducial marker kit, Civco, Maarn, the 
Netherlands) on and around the target, using 18-gauge 
introducer needles. Each fiducial marker measured 0.9 x 3.0 
mm in diameter and length, respectively. When performing 
the fiducial implantation, it is advised to keep a minimum 
of 20 mm spacing, and a minimum 15° angle between the 
fiducials. Moreover, the fiducials should not be more than 
50 to 60 mm away from the target.
This implantation procedure was usually performed within 
20 minutes. Two or three days after the implantation, a 
CyberKnife therapy planning radiograph was performed, 
followed by a CyberKnife planning CT for the simulation 
of radiation treatment in all the patients within a span 
of two weeks. CT was performed using a 4-slice MDCT 
scanner (Sensation 4, Siemens Medical System, Forchhein, 
Germany). The imaging parameters included a 4.0 x 2.5 mm 
section detector collimation, 120 kV, 145 mAs, 15 mm per 
second table speed, pitch of 6, and a 1 mm reconstruction 
interval.
 
Analysis
Upon review of the medical records CyberKnife therapy 
planning radiographs and the planning CT for the evaluation 
of procedure-related complications were performed. 
During and after the implantation, the major and minor 
procedure-related complications were documented. We only 
recorded the immediate complications until the time of the 
CyberKnife planning CT (within 2 weeks).
The major/minor complications were divided by the 
outcome and according to the SIR Classification System 
for Complications. Minor complications were divided 
into two types (A. No therapy and of no consequence, B. 
Nominal therapy and of no consequence; includes overnight 
admission for observation only). Major complications were 
divided into four types (C. Required therapy and minor 
hospitalization (< 48 hours), D. Required major therapy 
and an unplanned increase in the level of care, prolonged 
hospitalization (> 48 hours), E. Permanent adverse 
sequelae, F. Death). 
Also, research about whether the fiducial implantation 
was successful or not was carried out, and we reviewed 
the CyberKnife therapy planning radiographs and 
planning CT images. We defined technical success as the 
implantation enabled adequate treatment planning and 
CT simulation. The cases in which more than two fiducial 
markers overlapped, or reimplantation was needed due to 
an unexpected occurrence such as fiducial migration, were 
considered as technical failure.
 
RESULTS
Immediate Complication
When conducting 270 fiducial implantations in 77 
patients, there was one patient with major complication 
(1.3%) and 16 patients with minor complications (20.8%) 
(Table 2).
The patient with a major complication had previously 
undergone Whipple’s operation due to CBD cancer. A newly-
appeared, 3.7-cm, low-density mass in segment V of the 
liver on the follow up CT scan (this was presumed to be 
metastasis) was found. The patient was implanted with 
four fiducial markers under trans-abdominal ultrasound-
guidance for the planning of CyberKnife therapy. Following 
the implantation, the patient complained of local pain in 
the insertion site. Analgesics and conservative treatment 
were performed; however, after 11 hours from the time of 
fiducial marker insertion, the patient’s body temperature 
rose to 38.6°C and dyspnea as well as right flank pain 
developed. The patient’s pleural effusion gradually increased 
Table 2. Immediate Complications of Ultrasound-Guided 
Fiducial Marker Implantation
Complication No. of Patients (%) 
Trans-abdominal USG-guided  63 (100)
No complications 51 (81.0)
Major complications 1 (1.6)
Minor complications 11 (17.4)
Abdominal pain-no analgesics  4 (6.3)
Abdominal pain-analgesics 5 (7.9)
Fever  1 (1.6)
Skin bullae 1 (1.6)
Trans-rectal USG-guided 14 (100)
No complications 9 (64.3)
Major complications 0 (0)
Minor complications 5 (35.7)
Fever 1 (7.1)
Pain 2 (14.3)
Transient voiding difficulty 1 (7.1)
Transient hematuria 1 (7.1)
Total 77 (100)
No complications 60 (77.9)
Major complications 1 (1.3)
Minor complications 16 (20.8)Korean J Radiol 13(3), May/Jun 2012 kjronline.org 310
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during the five days after the procedure. Following this, 
percutaneous-catheter insertion was performed for the 
pleural effusion. The patient’s condition gradually improved 
after percutaneous-catheter insertion. The CyberKnife 
planning CT was taken two weeks after fiducial implantation 
and the CT scan showed a newly appeared subcapsular fluid 
collection around the liver and biliary dilatation of the 
peripheral intrahepatic duct, which was suspected to be a 
biloma. However, the patient did not complain about further 
symptoms. The patient suffered from a few complications, 
yet the four fiducial markers were well located in the target 
tumor. It could be seen on the follow-up CT that the tumor 
decreased in size from about 3.7 cm to 2.0 cm at one 
month after the CyberKnife treatment (Fig. 1).
Sixteen patients (20.8%) had minor complications that 
only required overnight admission for observation and no 
or minimal therapy. Eleven patients had abdominal pain, 
four of which did not require specific treatment during the 
follow-up period. Moreover, two patients had mild fever 
that also did not require any follow-up treatment, and 
Fig. 1. Major complications. 
61 year-old-man with hepatic metastasis from recurrent comon bile duct cancer underwent successful implantation of fiducial markers around 
tumor. After procedure, patient complained of fever, dyspnea and right flank pain. CT (A) shows well-located fiducial marker (arrowhead) around 
hepatic metastatic tumor and more upper level CT (B) shows ductal dilatation (arrow) of peripheral intrahepatic bile duct. Also, note pleural 
effusion and subcapsular hematoma around portion of liver dome (not seen).
A B
Fig. 2. Fiducial migration. 
59 year-old-man with HCC in liver had undergone implantation of 4 fiducial makers around tumor. Two weeks later, only 3 fiducial markers 
(arrowheads) were found around HCC on CyberKnife planning CT scan (A) and missing fiducial marker (arrow) was found in pelvic cavity on 
scanogram (B).
A
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one patient had mild transient bullae change at the skin 
puncture site and did not require specific treatment other 
than a simple dressing. Lastly, there were two patients with 
nonspecific urinary symptoms.
As guides for transrectal ultrasound, fiducial markers were 
inserted into fourteen patients. Among them, nine patients’ 
fiducial markers were inserted to the prostate gland, and 
the other five into the metastatic lymph nodes in the pelvic 
cavity. When these implantations were conducted, one 
patient had transient hematuria that did not last for more 
than a day and it did not require any specific treatment. 
Another patient had transient voiding difficulty that 
required nelaton catheter voiding. None of the patients had 
major complications that required long-term hospitalization.
Technical Aspect
Of the 270 fiducial implantations, 261 (96.7%) were 
considered to be successful. However, the migration of 
fiducial markers was observed for six implantations (2.2%) 
in six patients. In the case of the planning CT scanning for 
the actual treatment, since the treatment is not feasible 
when fiducial markers migrate more than 6 cm from the 
target, the procedure needs to be re-done, which was 
considered a technical failure in this study. Of the six failed 
implantations, five were implanted for intraabdominal 
metastatic lymph nodes and one of them was implanted for 
hepatocellular carcinoma (Fig. 2). 
We also observed a failure to discriminate fiducial 
markers for three implantations (1.1%). Each was 
implanted for an intra-abdominal metastatic lymph node 
(Fig. 3), cholangiocarcinoma and pancreatic body cancer, 
respectively. Among total 77 patients, six patients (7.8%) 
required additional procedures for reimplantation of fiducial 
Fig. 3. Failure of fiducial discrimination. 
55 year-old-man had metastatic lymph node from rectal cancer in right pelvic cavity. We implanted 4 fiducial markers within lesion by trans-
rectal ultrasound-guidance. Two of markers (between number 1 and number 3, arrowheads) overlapped on CyberKnife planning radiograph (A), 
while two overlapped fiducial markers (arrowheads) are also seen on CyberKnife planning CT scan (B).
A B
Table 3. Technical Success Rate of Ultrasound-Guided 
Fiducial Marker Implantation
Technical Aspect
No. of 
Patients (%)
No. of 
Fiducials (%)
Trans-abdominal USG guided  63 222
Successfully implanted 
fiducials
56 (88.9) 215 (96.8)
Technical failure 7 (11.1) 7 (3.2)
Migrated fiducials 5 (7.9) 5 (2.3)
Discrimination failed 
fiducials
2 (3.2) 2 (0.9)
Trans-rectal USG-guided 14 48
Successfully implanted 
fiducials
12 (85.7) 46 (95.8)
Technical failure 2 (14.3) 2 (4.2)
Migrated fiducials 1 (7.1) 1 (2.1)
Discrimination failed 
fiducials
1 (7.1) 1 (2.1)
Total
Successfully implanted 
fiducials
68 (88.3) 261 (96.7)
Technical failure 9 (11.7) 9 (3.3)
Migrated fiducials 6 (7.8) 6 (2.2)
Discrimination failed 
fiducials
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markers, and one of them was reimplanted under a CT-
guidance (Table 3).
 
DISCUSSION
Stereotactic radiosurgery was primarily developed in 
Sweden in the 1950s (4). Radiosurgery is the precise 
application of a high dose of radiation in a precisely defined 
target volume while protecting the surrounding healthy 
tissue. In the beginning, this method was only used for 
brain lesions. Stereotactic radiosurgery previously utilized 
a stereotactic body frame to compensate for respiratory 
motion. This was uncomfortable to patients because 
treatment involved a long immobilization period (5).
The CyberKnife system is a recent, frameless stereotactic 
radiosurgery system which allows real-time tracking of 
tumors during the entire treatment cycle through the 
synchrony system. This system uses a combination of 
internal fiducial markers around the target tumor and light 
emitting optical diodes. It can predict the internal tumor 
location by coupling the motion of the light emitting 
optical diodes and the internal fiducial markers. It also 
adjusts for respiratory variations in real-time. The real-time 
imaging tracking of the CyberKnife system allows patient 
movements to be tracked with a spatial accuracy of 1 mm (1, 
6).
Implanting internal fiducial markers into or around 
a tumor is an important procedure for image-guided 
radiotherapy, such as CyberKnife therapy. Three to six 
markers are recommended to be implanted. A fiducial marker 
is less than 2.0 mm in diameter and is a spherical internal 
radiologic land marker. For bio-compatibility and good 
contrast on X-ray images, the marker is made out of gold 
(99.99% purity) (1, 6-9).
The marker is introduced percutaneously via an 18-gauge 
introducer needle. Usually, the marker implantation is 
guided by a CT scan (2, 3), but is occasionally guided 
by trans-abdominal or trans-rectal ultrasound for intra-
abdominal lesions. Ultrasound provides real-time monitoring 
of the whole procedure and more comfortable handling 
during an intra-abdominal procedure. Therefore, we thought 
ultrasound-guided implantation could raise the success rate 
over currently used methods. Ultrasound can also reduce 
radiation hazard compared to a CT-guided procedure. 
When performing a fiducial implantation, it is advised 
to keep a minimum spacing of 20 mm and a minimum 15° 
angle between the fiducials. Moreover, the fiducials should 
not be more than 50-60 mm away from the targets (10, 11), 
if the markers are superimposed on each other in the 45° 
oblique views, the Cyber Knife system will interpret them as 
a single marker (12). Therefore, the implantation should be 
executed with consideration of all these circumstances.
As for the results, the overall major complication rate 
was 1.3% and the minor complication rate was 20.8%. 
The major complication rate was generally comparable 
to the previously reported complication rate (2.0%) of 
the image-guided percutaneous biopsy (13), whereas any 
major complication by trans-rectal ultrasound-guided 
implantation was not witnessed. A minor complication was 
defined as a complication that had no negative impact on a 
particular treatment. That is, the complications associated 
with ultrasound-guided fiducial marker implantations were 
not regarded as dangerous compared to other types of 
biopsies. Also, the major complication rate was lower than 
that of the previously reported CT-guided fiducial marker 
implantation study by Kothary et al. (3), which found a 5% 
complication rate (7 out of 139 implantations).
For the evaluation of technical success, the study 
demonstrated the migration of six fiducial markers (2.2%) 
in six patients, as well as three cases of implantation (1.1%) 
that failed to allow discriminating fiducial marker. As a 
result, the successful implantation rate was 96.1%. This 
was similar to the previously reported success rate of CT-
guided implantation (95.7%) (3). The reason for the high 
rate of migrations was possibly from the movement of the 
mesentery (five implantations). Another case of migration 
involved a small hepatocellular tumor located at the 
adjacent hepatic capsule. 
Overall, 7.8% (six patients) of all the patients required 
additional implantations of fiducial markers. While there 
have not been any previous reports on the reimplantation 
rate, the above figure implies that a repeated procedure 
for a relatively high number of patients was needed for 
comparison to the complication rate. Three out of these six 
patients had been treated for intra-abdominal lymph node 
metastases: two for liver implantation and the other for 
pancreas implantation.
Additionally, as ultrasound lacks spatial accuracy in three-
dimensions compared to CT scans, the chances of failing 
to discriminate fiducial markers seems relatively high. The 
risk of discrimination failure seemed to increase when we 
implanted more than three fiducial markers. Hence, we 
should be more cautious when implanting the 3rd and 4th 
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Our study had several limitations. First, it was a 
retrospective review from a single institution. Thus, it 
could include a selection and interpretation bias. There 
were a relatively large number of patients with metastatic 
lymph nodes compared with the number of patients with 
a primary tumor. Our institution is a tertiary center where 
end stage patients and recurrent patients are transferred 
from other hospitals. The large number of patients with 
metastatic lymph nodes could have influenced the results 
of the technical success rate due to the increased rate 
of mesenteric implantation. However, most CyberKnife 
treatment is practiced at a tertiary center. So, the overall 
patient demographics could be similar to ours. 
Second, we only included immediate complications from 
the time of planning the CyberKnife CT until two weeks 
after the fiducial marker implantation . We did not record 
long term complications beyond two weeks after CyberKnife 
therapy. We believed that any longer term complications 
were not remarkably associated with the US-guided 
procedure.
The growing number of CyberKnife treatments has 
recently expanded the role of radiologists who conduct 
fiducial marker implantations. While studies on the CT-
guided practices can be found, the safety of US-guided 
implantation and its technical success rate have not been 
previously reported.
Ultrasound-guided fiducial marker implantation is a safe 
surgical operation that shows a similar complication rate, 
as well as high technical success rate to that of the CT-
guided practice or biopsy. Nonetheless, as we had a high 
reimplantation rate; radiologists must pay careful attention 
when performing ultrasound-guided fiducial marker 
implantations. 
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